
Mark McCormack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6326019/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. New England Journal of Medicine, 2011, 364, 1134-1143.	13.9	815
2	Natural selection on <i>EPAS1</i> (<i>HIF2α</i>) associated with low hemoglobin concentration in Tibetan highlanders. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11459-11464.	3.3	708
3	Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2014, 13, 893-903.	4.9	264
4	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	2.6	237
5	TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function. Nature Genetics, 2014, 46, 516-521.	9.4	122
6	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	3.7	100
7	Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia. Journal of Applied Physiology, 2014, 116, 893-904.	1.2	97
8	Exome Sequencing Followed by Large-Scale Genotyping Fails to Identify Single Rare Variants of Large Effect in Idiopathic Generalized Epilepsy. American Journal of Human Genetics, 2012, 91, 293-302.	2.6	95
9	Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study. Lancet Neurology, The, 2018, 17, 699-708.	4.9	67
10	Genetic variation in <i>CFH</i> predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology, 2018, 90, e332-e341.	1.5	43
11	A genomeâ€wide association study of recipient genotype and mediumâ€ŧerm kidney allograft function. Clinical Transplantation, 2013, 27, 379-387.	0.8	39
12	Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics, 2012, 13, 399-405.	0.6	38
13	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	1.3	34
14	Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics, 2011, 12, 1429-1447.	0.6	31
15	A comparison of genomic diagnostics in adults and children with epilepsy and comorbid intellectual disability. European Journal of Human Genetics, 2020, 28, 1066-1077.	1.4	30
16	Testing association of rare genetic variants with resistance to three common antiseizure medications. Epilepsia, 2020, 61, 657-666.	2.6	22
17	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. Pharmacogenomics, 2020, 21, 325-335.	0.6	21
18	Assessing the role of rare genetic variants in drugâ€resistant, nonâ€lesional focal epilepsy. Annals of Clinical and Translational Neurology, 2021, 8, 1376-1387.	1.7	16

MARK MCCORMACK

#	Article	IF	CITATIONS
19	Influence of common SCN1A promoter variants on the severity of SCN1A â€related phenotypes. Molecular Genetics & Genomic Medicine, 2019, 7, e00727.	0.6	13
20	Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 2019, 4, 563-571.	1.3	12
21	The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer. Oncotarget, 2016, 7, 75518-75525.	0.8	12
22	A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam. Epilepsia, 2022, 63, 1563-1570.	2.6	11
23	Association of CYP3A variants with kidney transplant outcomes. Renal Failure, 2015, 37, 562-566.	0.8	9
24	A genomeâ€wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine. Epilepsia Open, 2019, 4, 102-109.	1.3	9
25	Symptomatology of carbamazepine―and oxcarbazepineâ€induced hyponatremia in people with epilepsy. Epilepsia, 2021, 62, 778-784.	2.6	9
26	De-novo mutations in patients with chronic ultra-refractory epilepsy with onset after age five years. European Journal of Medical Genetics, 2020, 63, 103625.	0.7	9
27	Development of a genomics module within an epilepsyâ€specific electronic health record: Toward genomic medicine in epilepsy care. Epilepsia, 2019, 60, 1670-1677.	2.6	7
28	Role of Common Genetic Variants for Drug-Resistance to Specific Anti-Seizure Medications. Frontiers in Pharmacology, 2021, 12, 688386.	1.6	6
29	Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy. Neurobiology of Aging, 2020, 92, 153.e1-153.e5.	1.5	4